SR604 Advances to Phase 3 in Hemophilia A and B
Shanghai RAAS disclosed on 17 September that SR604 entered a single arm multicenter Phase 3 study for prophylaxis in hemophilia A or B patients with or without inhibitors. The registered dose is 0.4 mg…
